CATALYST PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 5th, 2024 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
CATALYST PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of Debt SecuritiesIndenture • July 23rd, 2020 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Indenture, dated as of , among Catalyst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):
14,285,715 Shares Catalyst Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 28th, 2017 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
CONFIDENTIAL Patrick McEnany Chief Executive Officer Catalyst Pharmaceutical Partners, Inc.Catalyst Pharmaceutical Partners, Inc. • October 2nd, 2009 • Pharmaceutical preparations • New York
Underwriting AgreementUnderwriting Agreement • September 26th, 2006 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • New York
2,259,943 Shares CATALYST PHARMACEUTICAL PARTNERS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 8th, 2011 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • California
Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Roth Capital Partners, LLC (the “Underwriter”) an aggregate of 2,259,943 authorized but unissued shares (the “Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 6th, 2010 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 5, 2010, between Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), and the party which executes the signature page attached hereto as purchaser (the “Purchaser”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 12th, 2008 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 11, 2008, between Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
13,023,750 Shares Catalyst Pharmaceutical Partners, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 3rd, 2014 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 2nd, 2009 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 1, 2009, between Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
CATALYST PHARMACEUTICAL PARTNERS, INC. 8,800,000 shares of Common Stock PLACEMENT AGENT AGREEMENTCatalyst Pharmaceutical Partners, Inc. • September 5th, 2013 • Pharmaceutical preparations • California
Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), up to an aggregate of 8,800,000 authorized but unissued shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company hereby confirms its agreement with Roth Capital Partners, LLC (the “Placement Agent”) to act as Placement Agent in accordance with the terms and conditions hereof.
10,000,000 Shares Catalyst Pharmaceutical Partners, Inc. Common Stock UNDERWRITING AGREEMENTCatalyst Pharmaceutical Partners, Inc. • February 4th, 2015 • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • December 15th, 2006 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • Florida
This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of the 8th day of November, 2006 by and between Jack Weinstein (the “Employee”), and Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”).
RIGHTS AGREEMENT between CATALYST PHARMACEUTICAL PARTNERS, INC. and CONTINENTAL STOCK TRANSFER AND TRUST COMPANY as Rights Agent Dated as of September 20, 2011Rights Agreement • September 23rd, 2011 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • Delaware
This RIGHTS AGREEMENT, dated as of September 20, 2011 (this “Agreement”), is made by and between Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer and Trust Company (the “Rights Agent”).
NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • July 25th, 2006 • Catalyst Pharmaceutical Partners, Inc. • Florida
THIS AGREEMENT, entered into on October 1st, 2004 (the “Grant Date”), is made by and between Catalyst Pharmaceutical Partners, Inc., a Florida corporation (“Catalyst”) and Jack Weinstein, a Consultant to Catalyst, hereinafter referred to as “Optionee”:
Catalyst Pharmaceutical Partners, Inc. Coral Gables, Florida 33134 Gentlemen:Catalyst Pharmaceutical Partners, Inc. • September 5th, 2013 • Pharmaceutical preparations • New York
The undersigned (the “Investor”) hereby confirms its agreement with Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), as follows:
CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]1 LICENSE AGREEMENTLicense Agreement • January 4th, 2013 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • California
CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]1 THIRD AMENDMENT TO LEASEConfidential Treatment • August 7th, 2015 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of the 16th day of March, 2015 (the “Effective Date”), by and between CPT 355 ALHAMBRA CIRCLE, LLC, a Delaware limited liability company, successor in interest to 355 Alhambra Plaza, Ltd. (“Landlord”), and CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation (“Tenant”).
Text omitted and filed separately with the Securities and Exchange Commission/Confidential Treatment Requested under 17 C.F.R. Section 240.24b-2Development, License and Commercialization Agreement • December 26th, 2018 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into and effective as of December 18, 2018 (the “Effective Date”) by and between Endo Ventures Limited, an Irish company, with offices located at First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (“EVL”), and Catalyst Pharmaceuticals, Inc., a Delaware corporation, with offices located at 355 Alhambra Circle Suite 1250, Coral Gables, FL, USA (“Catalyst”).
CATALYST PHARMACEUTICAL PARTNERS, INC. 3,046,740 shares of Common Stock and Warrants to purchase up to 1,523,370 shares of Common Stock UNDERWRITING AGREEMENTCatalyst Pharmaceutical Partners, Inc. • October 28th, 2011 • Pharmaceutical preparations • California
Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Roth Capital Partners, LLC (the “Underwriter”) an aggregate of 3,046,740 authorized but unissued shares (the “Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company and (ii) warrants (the “Warrants”) to purchase up to 1,523,370 shares of Common Stock (the “Warrant Shares”). The form of the Warrant is attached hereto as Exhibit A. The Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities.”
LICENSE AGREEMENTLicense Agreement • September 2nd, 2009 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • Illinois
This Agreement made effective as of this 27 th day of August, 2009 (the “Effective Date”), by and between Northwestern University, an Illinois corporation having a principal office at 633 Clark Street, Evanston, Illinois 60208 (hereinafter referred to as “Northwestern”) and Catalyst Pharmaceutical Partners, Inc., a Delaware corporation having a principal office at 355 Alhambra Circle, Suite 1370, Coral Gables, FL, 33134 (hereinafter referred to as “Licensee”) (each a “Party” and collectively the “Parties”).
TERMINATION AGREEMENTTermination Agreement • November 13th, 2013 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations
This Termination Agreement (the “Agreement”), is made and entered into as of the latest date of signature below and is effective as of October 1, 2013 (the “Effective Date”) by and between Brookhaven Science Associates, LLC (“Brookhaven”) and Catalyst Pharmaceutical Partners, Inc. (“Catalyst”).
ContractNote and Note Purchase Agreement • October 31st, 2012 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • New York
THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO REGISTRATION, QUALIFICATION OR EXEMPTION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS.
FIFTH AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • June 24th, 2016 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into as of this 23rd day of June, 2016, by and between CATALYST PHARMACEUTICALS, INC. (f/k/a Catalyst Pharmaceutical Partners, Inc.), a Delaware corporation (“Company”), and PATRICK J. MCENANY (“Employee”).
AMENDMENT NO. 1 TO CONSULTING AGREEMENTConsulting Agreement • January 3rd, 2007 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO CONSULTING AGREEMENT (“Amendment”) is executed this 5th day of December, 2006, effective as of the 3rd day of January, 2007, by and between CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation (“Company”) and Charles O’Keeffe (“Consultant”).
LICENSE AND ASSET PURCHASE AGREEMENTLicense and Asset Purchase Agreement • July 12th, 2022 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AND ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 11, 2022 (the “Execution Date”), by and between JACOBUS PHARMACEUTICAL COMPANY, INC., a New Jersey corporation with offices located at IRL Building, 31 Schalks Crossing Road, Plainsboro, NJ (“Jacobus”) and CATALYST PHARMACEUTICALS, INC., a Delaware corporation with offices located at 355 Alhambra Circle, Suite 801, Coral Gables, FL (“Catalyst”). Jacobus and Catalyst are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EXHIBIT J FORM OF TRANSITION SERVICES AGREEMENT TRANSITION SERVICES AGREEMENT by and between Eisai Inc. and Catalyst Pharmaceuticals, Inc. Dated as of [•]Transition Services Agreement • December 22nd, 2022 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Transition Services Agreement (this “Agreement”) dated as of [•] (the “Effective Date”), by and between Eisai Inc., a Delaware corporation (“Seller”) and Catalyst Pharmaceuticals, Inc., a Delaware corporation (“Buyer”). Seller and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SIXTH AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 31st, 2018 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations
This SIXTH AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into as of this 25th day of May, 2018, by and between CATALYST PHARMACEUTICALS, INC., a Delaware corporation (“Company”) and PATRICK J. MCENANY (“Employee”).
FOURTH AMENDMENT TO LEASELease • August 17th, 2018 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations
This Fourth Amendment to Lease (this “Fourth Amendment”) is made and entered into by and between PRII 355 ALHAMBRA CIRCLE, LLC, a Delaware limited liability company (“Landlord”), as successor-in-interest to 355 Alhambra Plaza, Ltd., a Florida limited partnership (“Original Landlord”) and to CPT 355 Alhambra Circle, LLC, a Delaware limited liability company (“Intermediate Landlord”), and CATALYST PHARMACEUTICALS, INC. (f/k/a Catalyst Pharmaceutical Partners, Inc.), a Delaware corporation (“Tenant”), effective as of the date this Fourth Amendment is executed by Landlord, as evidenced on the signature page attached hereto (the “Effective Date”).
AGREEMENTAgreement • May 15th, 2008 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • Florida
This AGREEMENT (this “Agreement”) is made and entered into this 30th day of April, 2008, effective the [1st day of May], 2008 (the “Effective Date”) by and between CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation, with offices located in Coral Gables, Florida (the “Company”) and ANDREW FORMAN, an individual resident of the state of Virginia (“Forman”).
Certain identified information has been excluded from this exhibit because it is both (i) not material, and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been redacted....Separation Agreement and General Release • February 28th, 2024 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • Florida
This Separation Agreement and General Release (“Agreement”) is entered into between Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) and Alicia Grande (“Employee”) (each individually, a “Party”, and collectively, the “Parties”). The Parties agree as follows:
AGREEMENTAgreement • September 1st, 2006 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • Florida
This AGREEMENT (this “Agreement”) is made and entered into this 25th day of August, 2006, effective the 1st day of September, 2006 (the “Effective Date”) by and between CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation, with offices located in Coral Gables, Florida (the “Company”) and CHARLES W. GORODETZKY, M.D., Ph.D., an individual resident of the state of Missouri (“Gorodetzky”).
LICENSE AGREEMENTLicense Agreement • March 30th, 2012 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • New York
NEW YORK UNIVERSITY (“NYU”), a corporation organized and existing under the laws of the State of New York and having a place of business at 70 Washington Square South, New York, NY 10012,
Exhibit H Form of Supply Agreement SUPPLY AGREEMENT between EISAI CO., LTD. and CATALYST PHARMACEUTICALS, INC. Dated as of [ • ], 2022Supply Agreement • December 22nd, 2022 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Supply Agreement (this “Agreement”) is made and entered into effective as of [ • ], 2022 (the “Effective Date”) by and between Eisai Co., Ltd., a corporation organized under the laws of Japan (“Seller”), and Catalyst Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Buyer”). Seller and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • September 9th, 2022 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations
This EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into as of this 8th day of September, 2022, by and between CATALYST PHARMACEUTICALS, INC., a Delaware corporation (“Company”) and PATRICK J. MCENANY (“Employee”).
